Nanoscale, antigen encounter-dependent, IL-12 delivery by CAR T cells plus PD-L1 blockade for cancer treatment.

ABSTRACT:

Background

Chimeric antigen receptor (CAR)-T cell therapies for the treatment of hematological malignancies experienced tremendous progress in the last decade. However, essential limitations need to be addressed to further improve efficacy and reduce toxicity to assure CAR-T cell persistence, trafficking to the tumor site, resistance to an hostile tumor microenvironment (TME), and containment of toxicity restricting production of powerful but potentially toxic bioproducts to the TME; the last could be achieved through contextual release upon tumor antigen encounter of factors capable of converting an immune suppressive TME into one conducive to immune rejection.

Methods

We created an HER2-targeting CAR-T (RB-312) using a clustered regularly interspaced short palindromic repe

SUBMITTER: Yang Z 

PROVIDER: S-EPMC9976446 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature